Tandem Diabetes Care, Inc. (TNDM) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $16.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 1.50; Below-average business quality.
Tandem Diabetes Care designs and commercializes insulin pumps (t:slim X2, Tandem Mobi with Control-IQ+) serving nearly 500,000 people with diabetes in 25+ countries. Revenue comes from pump sales and recurring single-use supplies (cartridges, infusion sets) through US/Canada... Read more
Sell if holding. Engine safety override at $16.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 1.50; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 59. Score 5.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About Tandem Diabetes Care, Inc.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care commercializes two insulin pump platforms — the t:slim X2 and Tandem Mobi — both featuring Control-IQ+ automated insulin delivery technology cleared by the FDA in March 2025 for type 2 patients aged 18 and older, building on its type 1 clearance for patients aged 2 and older. The company assembles pumps at its San Diego, California facility and serves nearly 500,000 people in more than 25 countries. Mobi with Android control launched in December 2025, extending the platform further.
Revenue comes from durable pump sales and recurring single-use supplies — insulin cartridges and infusion sets replaced every three to seven days. In the U.S. and Canada, distribution runs through independent distributors for order fulfillment while Tandem's own sales, clinical, and customer support teams manage the patient relationship. The company is transitioning toward a pharmacy benefit reimbursement model as an alternative to the traditional durable medical equipment channel, which could reduce upfront pump payments while increasing recurring supply revenue per customer. Unomedical A/S, a ConvaTec subsidiary, manufactures all commercially marketed infusion sets as a sole-source supplier. Two independent distributors each represented more than 10% of worldwide 2025 sales. Competitors include Insulet, Medtronic, Beta Bionics, mylife, and Sequel.
Show full overview
The FDA's December 2025 finalization of competitive bidding for insulin pumps and continuous glucose monitors under CMS — alongside a proposed shift to monthly rental reimbursement — introduces structural pricing pressure to Tandem's U.S. durable medical equipment channel. The company's ACE pump and iAGC classification under FDA Class II special controls provides a streamlined regulatory path but requires ongoing satisfaction of those controls, or products revert to the full PMA process. Tandem also depends on CGM integrations with Dexcom and Abbott, which can be terminated on relatively short notice; in May 2026, the company terminated Chief Commercial Officer Mark Novara without cause, leaving the commercial leadership role vacant.
See also: Healthcare · Medical Devices
From Tandem Diabetes Care, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-06-15Recent Developments — Tandem Diabetes Care, Inc.
Latest news
- NEWS Tandem Diabetes Care Receives CE Mark For Expanded Indications Of Its Automated Insulin Delivery Systems In Europe — benzinga Jun 5, 2026 positive
- NEWS Wells Fargo Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $27 — benzinga Jun 1, 2026 positive
- NEWS Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17 — benzinga May 28, 2026 negative
- NEWS B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25 — benzinga May 18, 2026 neutral
- NEWS This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga May 12, 2026
Generated 2026-06-17T09:12:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertwo independent distributors10-K Item 1: 'For the year ended December 31, 2025, two independent distributors each accounted for more than 10% of our worldwide sales.'
- HIGHSupplierUnomedical A/S10-K Item 1: 'we purchase all of our currently marketed infusion sets from a third-party supplier, Unomedical A/S, a subsidiary of the ConvaTec Group.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Volatile — 8.7% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -9.2%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 1.50; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 59. Prior stop was $15.47. Score 5.3/10, moderate confidence.
Take-profit target: $26.28 (+58.0% upside). Prior stop was $15.47. Stop-loss: $15.47.
Concentration risk — Customer: two independent distributors; Concentration risk — Supplier: Unomedical A/S; Quality below floor (3.1 < 4.0).
Tandem Diabetes Care, Inc. trades at a P/E of N/A (forward 282.6). TrendMatrix value score: 7.7/10. Verdict: Sell.
29 analysts cover TNDM with a consensus score of 3.8/5. Average price target: $29.
What does Tandem Diabetes Care, Inc. do?Tandem Diabetes Care designs and commercializes insulin pumps (t:slim X2, Tandem Mobi with Control-IQ+) serving nearly...
Tandem Diabetes Care designs and commercializes insulin pumps (t:slim X2, Tandem Mobi with Control-IQ+) serving nearly 500,000 people with diabetes in 25+ countries. Revenue comes from pump sales and recurring single-use supplies (cartridges, infusion sets) through US/Canada distributors, with international markets transitioning to direct sales. Two US distributors each exceeded 10% of worldwide sales in 2025.